AstraZeneca Pharma India maintains growth momentum with a strong start to FY2026–27

$ASTRAZEN AstraZeneca Pharma India Limited reported robust growth for Q1 FY2026–27, achieving a 30% increase in total revenue from operations to INR 6,828 million, driven by strong performance across Oncology, Biopharmaceuticals, and Rare Disease segments. The company secured key regulatory approvals for new therapies, expanded scientific engagement, and advanced strategic partnerships, including AI-enabled lung cancer screening and initiatives in cardiovascular and kidney care. Recognized for medical and employee excellence, AstraZeneca continues to focus on innovation, expanding access to healthcare, and sustainable long-term value creation in India.